Actively Recruiting
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours
Led by Wuxi People's Hospital · Updated on 2024-05-28
200
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1/PD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.
CONDITIONS
Official Title
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18-75 years
- Histologically- or cytologically-confirmed advanced solid tumor(s) with progression or ineligibility for standard therapy
- At least one measurable lesion per RECIST 1.1 criteria
- ECOG performance status score of 0-2 and life expectancy longer than 12 weeks
- Women of childbearing age must have a negative pregnancy test within 7 days before treatment
- Patients and partners of childbearing age must agree to use medically recognized contraception during treatment and for at least 6 months after the last dose
- Voluntary participation with signed informed consent, good compliance, and cooperation with follow-up
You will not qualify if you...
- Diagnosis of central nervous system leukemia
- White blood cell count of 50 x 10^9/L or higher, or rapid disease progression preventing completion of treatment
- Uncontrollable fungal, bacterial, viral, or other infections requiring isolation
- Positive for HIV, HBV, or HCV
- Diseases or lesions of the central nervous system such as stroke, epilepsy, or dementia
- Recent heart conditions including myocardial infarction, angiography or stents, active angina, cardiopathic asthma, or cardiovascular lymphocytic infiltrates within 12 months
- Severe coagulation problems or use of anticoagulation therapy
- Use of systemic corticosteroids or immunosuppressive agents within 2 weeks prior to study drug administration
- COVID-19 infection within 2 weeks prior to study drug administration
- Any serious uncontrolled disease or condition deemed unsuitable by the investigator
- Other conditions considered unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wuxi People's Hospital
Wuxi, Jiangsu, China, 214043
Actively Recruiting
Research Team
P
Peihua Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here